Component
Sleep latency, measurement specified by study
Sleep latency, measurement specified by study. Species, exposure and limitations are retained in each linked claim.
3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Latency to stage 2 sleep decreased by about 14 minutes compared with placebo.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/melatonin-research/23024438.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0f886545db45f7067ce68991935dcc3715082dbe31898c939eb64b015d3581f3", "start_char": 0, "end_char": 2402, "text_sha256": "0f886545db45f7067ce68991935dcc3715082dbe31898c939eb64b015d3581f3"}
- experimental_model
- Randomized double-blind placebo-controlled trial
- exposure
- 2.5 mg melatonin nightly for three weeks
- limitations
- Small selected group; does not prove every beta-blocker user is deficient or that all low-melatonin states respond identically.
- nutrient_topic
- Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
- organism
- Hypertensive patients taking atenolol or metoprolol; 15 analyzed
- plain_language
- The study measured a specific polysomnographic endpoint.
- primary_references
- [melatonin-p23024438] Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/23024438/ DOI: 10.5665/sleep.2122
- tissue_or_cell_type
- Polysomnographic sleep
Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1020–1031
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled trial · source_derived_draft · unverified_draft
### melatonin-beta-blocker-latency Latency to stage 2 sleep decreased by about 14 minutes compared with placebo. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The study measured a specific polysomnographic endpoint. organism: Hypertensive patients taking atenolol or metoprolol; 15 analyzed tissue_or_cell_type: Polysomnographic sleep experimental_model: Randomized double-blind placebo-controlled trial limitations: Small selected group; does not prove every beta-blocker user is deficient or that all low-melatonin states respond identically. exposure: 2.5 mg melatonin nightly for three weeks evidence_span: {"source_cache": "artifacts/melatonin-research/23024438.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0f886545db45f7067ce68991935dcc3715082dbe31898c939eb64b015d3581f3", "start_char": 0, "end_char": 2402, "text_sha256": "0f886545db45f7067ce68991935dcc3715082dbe31898c939eb64b015d3581f3"} [melatonin-p23024438] Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/23024438/ DOI: 10.5665/sleep.2122
Complete structured claim and evidenceSleep latency was unchanged in the boys-with-ADHD trial.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/theanine-research/22214254.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c4233ab5e7f87272614c99ebced46c55f732b71dc105c6e7adc56e433be57871", "start_char": 0, "end_char": 2347, "text_sha256": "c4233ab5e7f87272614c99ebced46c55f732b71dc105c6e7adc56e433be57871"}
- experimental_model
- Randomized double-blind placebo-controlled actigraphy trial
- exposure
- 400 mg/day for six weeks; stimulant treatment stratified
- limitations
- Short pediatric study in a specific population. Does not establish treatment of ADHD core symptoms or a general pediatric recommendation.
- nutrient_topic
- L-Theanine research collection; topical membership is not evidence of a direct dietary effect. · L-Theanine
- organism
- 98 boys aged 8-12 with ADHD
- plain_language
- Different sleep outcomes need separate entries.
- primary_references
- [theanine-p22214254] The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. (2011). https://pubmed.ncbi.nlm.nih.gov/22214254/
- tissue_or_cell_type
- Objective sleep monitoring
L-Theanine: metabolism, neural signaling, nutrient connections and human outcomes (2026-09-17) · lines 1173–1184
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled actigraphy trial · source_derived_draft · unverified_draft
### theanine-adhd-latency-null Sleep latency was unchanged in the boys-with-ADHD trial. Condition category: normal nutrient_topic: L-Theanine research collection; topical membership is not evidence of a direct dietary effect. plain_language: Different sleep outcomes need separate entries. organism: 98 boys aged 8-12 with ADHD tissue_or_cell_type: Objective sleep monitoring experimental_model: Randomized double-blind placebo-controlled actigraphy trial limitations: Short pediatric study in a specific population. Does not establish treatment of ADHD core symptoms or a general pediatric recommendation. exposure: 400 mg/day for six weeks; stimulant treatment stratified evidence_span: {"source_cache": "artifacts/theanine-research/22214254.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c4233ab5e7f87272614c99ebced46c55f732b71dc105c6e7adc56e433be57871", "start_char": 0, "end_char": 2347, "text_sha256": "c4233ab5e7f87272614c99ebced46c55f732b71dc105c6e7adc56e433be57871"} [theanine-p22214254] The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. (2011). https://pubmed.ncbi.nlm.nih.gov/22214254/
Complete structured claim and evidenceThe subjective sleep latency PSQI subscale improved relative to placebo.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/theanine-research/31623400.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e3120b65030838e8e5c127d357dffecc43605422d36545b0393cda9fd9f6b4af", "start_char": 0, "end_char": 1494, "text_sha256": "e3120b65030838e8e5c127d357dffecc43605422d36545b0393cda9fd9f6b4af"}
- experimental_model
- Randomized placebo-controlled crossover trial
- exposure
- 200 mg/day for four weeks
- limitations
- Small study and multiple endpoints. Within-group mood or cognition improvements are not automatically placebo-controlled effects.
- nutrient_topic
- L-Theanine research collection; topical membership is not evidence of a direct dietary effect. · L-Theanine
- organism
- 30 adults without major psychiatric illness
- plain_language
- This records a questionnaire subscale, not a measured increase in deep sleep.
- primary_references
- [theanine-p31623400] Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. (2019). https://pubmed.ncbi.nlm.nih.gov/31623400/ DOI: 10.3390/nu11102362
- tissue_or_cell_type
- Subjective sleep questionnaires
L-Theanine: metabolism, neural signaling, nutrient connections and human outcomes (2026-09-17) · lines 1082–1093
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled crossover trial · source_derived_draft · unverified_draft
### theanine-sleep-latency The subjective sleep latency PSQI subscale improved relative to placebo. Condition category: normal nutrient_topic: L-Theanine research collection; topical membership is not evidence of a direct dietary effect. plain_language: This records a questionnaire subscale, not a measured increase in deep sleep. organism: 30 adults without major psychiatric illness tissue_or_cell_type: Subjective sleep questionnaires experimental_model: Randomized placebo-controlled crossover trial limitations: Small study and multiple endpoints. Within-group mood or cognition improvements are not automatically placebo-controlled effects. exposure: 200 mg/day for four weeks evidence_span: {"source_cache": "artifacts/theanine-research/31623400.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e3120b65030838e8e5c127d357dffecc43605422d36545b0393cda9fd9f6b4af", "start_char": 0, "end_char": 1494, "text_sha256": "e3120b65030838e8e5c127d357dffecc43605422d36545b0393cda9fd9f6b4af"} [theanine-p31623400] Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. (2019). https://pubmed.ncbi.nlm.nih.gov/31623400/ DOI: 10.3390/nu11102362
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.